Envue Medical (FEED) announced that the Nasdaq Hearings Panel denied its request for continued listing, leading to a 23.20% after-hours stock drop. The company's shares will be suspended from Nasdaq and begin trading on the OTC Markets, signaling a significant downgrade in market visibility and liquidity.
Envue Medical (FEED) announced that the Nasdaq Hearings Panel denied its request for continued listing on the Nasdaq Capital Market. This decision means FEED's shares will be suspended from Nasdaq and will begin trading on the OTC Markets, effective September 16. This is a significant negative event for the company as it typically leads to reduced liquidity, lower investor confidence, and often a lower valuation due to the perception of increased risk and less stringent reporting requirements on OTC markets. While the company states business operations are unaffected, the immediate 23% after-hours drop and the 98.88% decline over the past year indicate severe investor concern. Traders should be aware of the increased volatility and potential for further downside as the stock transitions to a less regulated exchange, although the company is evaluating appeal options.